Elixinol Wellness Limited (EXL), an ASX-listed company, is involved in the global hemp industry, innovating, marketing, and selling hemp and other plant-derived food, skincare, and nutraceutical products.
| ASX Code | EXL |
| Website | N/A |
| Industry/Sector | Personal Products |
| Market Cap ($M) | 2 |
| EXL Share Price | $0.006 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.006 |
| EXL Share Price Movement | - ( No change ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Final | 10.5¢ | 100% | 4 Sep 2006 | 15 Sep 2006 | - | - | - |
| Interim | 13¢ | 100% | 28 Feb 2006 | 14 Mar 2006 | - | - | - |
| Final | 16¢ | 100% | 29 Aug 2005 | 16 Sep 2005 | - | - | - |
See all dividends from Elixinol Wellness Limited (EXL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$5.07 | -$2.00 | 86.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.64 | -$1.10 | -86.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$5.94 | -$7.90 | -58.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Elixinol Wellness Limited (EXL) | $2M | 0.8679 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Name | Position | Start Date |
|---|---|---|
| Ms Natalie Butler | Head of Marketing, Executive Director | 28 Mar 2024 |
| Mr Gavin Evans | Non-Executive Chairman, Non-Executive Director | 2 Dec 2025 |
| Ms Pauline Therese Gately | Non-Executive Director | 17 Aug 2023 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 2 Jun 2026 | EVANS, Gavin | Buy | Indirect Shares | 496,636 | $0.009 | $4,221.406 |
| 30 Dec 2025 | EVANS, Gavin | Buy | Indirect Shares | 397,010 | $0.010 | $3,820.850 |
| 31 May 2024 | FENLON, David (Dave) | Issued | Related Securities | 3,752,345 | $0.005 | $19,999.999 |
See all changes in directors' interest & trades for Elixinol Wellness Limited (EXL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Adam Dimitropoulos | Group Chief Financial Officer |
| Tony Di Pietro | Joint Company Secretary |
| Mariia Skorikova | Joint Company Secretary |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Elixinol Wellness Limited (EXL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 52,812,092 (12.76%) | Freedom Trader Pty Ltd |
| 12,500,000 (6.40%) | Stuart Reseck |
| 12,500,000 (5.70%) | Cutter Super Pty Ltd |
| Date | Event |
|---|---|
| 26 February 2027 | Report (Annual) |
| 26 February 2027 | Report (Prelim) |
| 28 August 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.